Medical AI is changing quickly—and so is the way regulators think about it. Unlike a traditional medical device with fixed specifications, an AI-enabled medical device or software tool can evolve after it reaches the market. Developers may retrain an algorithm, add new data, improve performance, or modify how the software supports clinical decisions.
That creates a regulatory challenge for the U.S. Food and Drug Administration (FDA): How can medical AI improve over time without weakening patient safety and clinical oversight?
The FDA’s evolving approach centers on a concept called a Predetermined Change Control Plan (PCCP). In August 2025, the FDA issued final guidance describing how manufacturers can use PCCPs for certain AI-enabled device software functions. The goal is to allow planned, validated improvements while maintaining reasonable assurance of safety and effectiveness.
For patients, clinicians, health systems, and healthcare technology companies, this could become an important part of how medical AI is developed and managed.
Why medical AI challenges traditional FDA regulation
The FDA regulates software that meets the definition of a medical device, including technologies that analyze medical images, detect disease, monitor patients, or support clinical decisions. Depending on the device and its risk, manufacturers may use regulatory pathways such as 510(k), De Novo, or Premarket Approval (PMA).
Traditional medical devices are often easier to evaluate because their characteristics remain relatively stable after approval.
AI is different.
An AI-enabled imaging system, for example, may be updated after developers obtain additional data. A model may be retrained to improve performance or adjusted after researchers identify differences across patient populations, imaging equipment, or clinical environments.
That creates an important distinction between a device that stays essentially the same and a software system that can evolve throughout its lifecycle.
The challenge becomes even greater when an algorithm performs differently in different healthcare environments. Patient demographics, disease prevalence, documentation practices, equipment, clinical workflows, and data quality can all influence AI performance.
An update that improves overall accuracy may not improve performance equally for every patient group.
What is an FDA Predetermined Change Control Plan?
A Predetermined Change Control Plan, or PCCP, is essentially a roadmap for planned changes to an AI-enabled medical device.
Under the FDA’s final guidance, a manufacturer can describe anticipated modifications in its marketing submission, along with the methodology it will use to develop, validate, implement, and assess those changes. If the FDA reviews and accepts the PCCP, certain changes covered by that plan may be implemented without requiring a separate marketing submission for every individual modification.
That does not mean manufacturers receive permission to change an AI system without limits.
The FDA emphasizes that planned changes should be defined and controlled. The changes also need to remain within the intended use or intended purpose of the original device.
In practical terms, the approach attempts to move away from asking:
“Does every software update require a completely new regulatory submission?”
Instead, the question becomes:
“Was this type of change anticipated, appropriately validated, and covered by an FDA-reviewed change-control plan?”
What should an AI change-control plan include?
A credible PCCP needs more than a promise that the algorithm will get better.
The FDA’s approach calls for manufacturers to describe the planned modifications, the methodology used to develop and validate them, and an assessment of their potential impact.
For example, a plan might address:
- Changes to an AI model or algorithm
- Retraining using new data
- Expansion within a defined patient population
- Changes to model inputs or outputs
- Performance testing before and after an update
- Monitoring for unexpected changes in performance
- Methods for detecting and addressing unacceptable performance
The FDA and international regulators have also emphasized that PCCPs should be focused and bounded, risk-based, evidence-based, transparent, and considered throughout the total product lifecycle.
That lifecycle perspective is particularly important for AI because the technology may continue evolving long after the original product reaches healthcare providers.
What does FDA medical AI regulation mean for patients?
For patients, the potential benefit is the ability to receive improvements to AI-enabled medical technologies without unnecessarily slowing innovation.
Imagine an AI tool used to analyze medical images. If developers identify a way to improve its ability to flag a particular finding, a structured change-control process could allow that improvement to move through a predefined validation pathway rather than starting the regulatory process from scratch.
But speed is only one consideration.
Patients also need confidence that AI systems work across the populations and environments in which they are used.
A model developed using data from one health system may not perform identically at another organization. Differences in demographics, clinical practices, equipment, and data quality can affect performance.
This is why transparency in healthcare AI matters. Patients and clinicians should understand what an AI tool is designed to do, what its limitations are, and where human judgment remains essential.
What healthcare providers and health systems should watch
For health systems, FDA oversight is only one part of responsible AI adoption.
Organizations should have their own governance processes for evaluating AI tools and subsequent updates.
Before accepting a significant AI update, healthcare organizations may want to understand:
- What changed?
- Why was the change made?
- What evidence supports the update?
- Was performance evaluated across relevant patient populations?
- Did the intended use change?
- Did the update affect false-positive or false-negative rates?
- Does the clinical workflow change?
- Do clinicians need additional training?
- How will performance be monitored after implementation?
This becomes particularly important when AI affects clinical triage, diagnosis, risk prediction, documentation, care management, or treatment decisions.
An algorithm can perform well technically and still create operational problems if it generates excessive alerts, changes clinical workflows, or encourages users to rely too heavily on automated recommendations.
The central trade-off: AI innovation versus accountability
The FDA’s PCCP approach recognizes an important reality: medical AI cannot necessarily be treated like a static product.
Requiring a new regulatory submission for every controlled and anticipated improvement could slow innovation. At the same time, giving developers unrestricted freedom to change an AI system after authorization could create significant safety and performance concerns.
The balance depends on the technology and its intended use.
An AI tool that organizes administrative information presents a different risk profile from software that interprets a chest X-ray, identifies a potentially life-threatening condition, or influences cancer treatment decisions.
The FDA’s current framework attempts to address that difference through a more structured, risk-based approach.
What happens after an AI medical device reaches the market?
The future of FDA medical AI regulation will increasingly involve what happens after a product reaches the market—not simply whether it was safe and effective at launch.
AI developers need processes for monitoring performance, identifying unexpected behavior, managing changes, and responding when an update does not perform as expected. The FDA’s broader AI work emphasizes lifecycle management and post-market considerations alongside premarket review.
For healthcare organizations, this means AI should increasingly be viewed as an ongoing clinical technology rather than a one-time software purchase.
For patients, the most important question may ultimately be simple:
Who is accountable when medical AI changes?
The promise of the FDA’s approach is not simply to make AI updates faster. It is to create a framework in which changes are planned, validated, monitored, and transparent.
As medical AI becomes more deeply embedded in healthcare, that balance between innovation and accountability will be critical to maintaining trust.
For a broader look at how consumers should evaluate AI-generated health information, see our article on whether you can trust healthcare advice from ChatGPT.
Thank you, You will be automatically subscribed to the our newsletter.